COVID-19 and IBD: Impact of Disease State and Biologics
In patients with IBD, management of immunosuppressive regimens, as well as safety and efficacy of vaccines, has raised many questions during the COVID-19 pandemic.
C. Andrew Kistler, MD, PharmD
Andy authors Cancer Therapy Advisor's "In the Clinic" column. He is a gastroenterologist with interests in GI oncology, immunotherapy, the gut microbiome, and clinical pharmacology.
